GLP-1 Medications for Men Over 50: Visceral Fat, Cardiovascular Risk, and What the Trials Show

Reviewed by Donald L. Gates, MD — Bariatric Medicine, practicing since 1999

Men over 50 face a specific constellation of weight-related health risks that differ in important ways from the challenges facing younger men or women of similar age. Visceral fat accumulation, metabolic syndrome, declining testosterone, and elevated cardiovascular risk are the dominant clinical concerns — and GLP-1 medications, backed now by trial data specifically addressing cardiovascular outcomes, are among the most effective pharmacological tools available for addressing these issues simultaneously.

This page is for men in their 50s, 60s, and beyond who are trying to understand whether GLP-1 therapy makes sense for their situation, what the evidence shows specifically for their demographic, and what to expect from physician-supervised treatment at Scale Solutions.

Visceral Fat and Metabolic Syndrome: The Core Issue

Not all fat is equally harmful. Subcutaneous fat — the fat you can pinch beneath the skin — is metabolically relatively benign. Visceral fat — the fat deposited within the abdominal cavity surrounding the liver, intestines, and other organs — is a different matter entirely. Visceral fat is metabolically active in a harmful way: it secretes inflammatory cytokines, contributes to insulin resistance, elevates free fatty acid levels, and is independently associated with cardiovascular disease, type 2 diabetes, and fatty liver disease.

Men over 50 accumulate visceral fat preferentially. This is partly a consequence of declining testosterone (which favors central fat deposition) and partly a function of decades of dietary patterns, reduced physical activity, and metabolic adaptation. The clinical marker for visceral fat accumulation is waist circumference: above 40 inches in men is defined as an elevated cardiometabolic risk threshold by most clinical guidelines.

Metabolic syndrome — defined as the combination of central obesity, high triglycerides, low HDL cholesterol, elevated fasting blood glucose, and high blood pressure — affects approximately 40% of men over 50 in the United States. Each component of metabolic syndrome independently increases cardiovascular and diabetes risk; together they multiply it. GLP-1 medications improve most components of metabolic syndrome simultaneously, through the combined effects of weight loss and direct metabolic action on the liver, pancreas, and cardiovascular system.

For more on how GLP-1 therapy specifically addresses insulin resistance, see our page on GLP-1 and insulin resistance.

Testosterone: Weight Loss Can Help Restore What Aging Diminishes

Testosterone levels decline gradually in men beginning in their 30s, with more noticeable effects in the 50s and beyond. This decline — sometimes called andropause, though it is more gradual and less discrete than female menopause — contributes to fatigue, reduced muscle mass, increased fat deposition, lower libido, and mood changes.

Obesity and low testosterone form a self-reinforcing cycle. Excess adipose tissue (fat) contains aromatase, an enzyme that converts testosterone to estradiol (an estrogen). Higher visceral fat mass leads to more testosterone conversion, lower circulating testosterone, and the associated symptoms. Lower testosterone, in turn, promotes further fat accumulation, particularly in the abdomen.

Clinically meaningful weight loss — whether from surgery, lifestyle change, or GLP-1 therapy — consistently raises testosterone levels in obese men with low-normal or frankly low testosterone. Studies have shown testosterone increases of 2-4 ng/dL per unit of BMI lost in some populations, with the effect most pronounced in men with initial BMI above 35. This is a genuine biological benefit of weight loss for this demographic, independent of any other medication.

Dr. Gates includes testosterone-related screening (total testosterone, if clinically indicated based on symptoms) in the initial evaluation for men presenting with obesity-related metabolic concerns.

The SELECT Trial: Semaglutide and Cardiovascular Outcomes

The most important clinical trial specifically addressing semaglutide in a cardiovascular context is the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), published in 2023. This was a large, randomized, placebo-controlled trial enrolling over 17,600 adults with obesity and established cardiovascular disease but without diabetes.

The primary finding: semaglutide 2.4mg weekly reduced the rate of major adverse cardiovascular events (MACE — defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 20% compared to placebo over a median follow-up of approximately 34 months. This is a clinically significant reduction in hard cardiovascular endpoints, not just a surrogate marker improvement.

For men over 50 with existing cardiovascular disease, known coronary artery disease, prior myocardial infarction, or peripheral arterial disease, this trial evidence directly supports the use of semaglutide not just for weight loss but as a tool to reduce cardiovascular event risk. This reframes the conversation: GLP-1 therapy for men in this demographic is not merely cosmetic weight management — it is cardiovascular risk reduction with FDA-recognized data.

Erectile Function: The Weight Loss Benefit Nobody Talks About

Erectile dysfunction (ED) is significantly more prevalent in obese men and in men with metabolic syndrome. The mechanisms are multiple: endothelial dysfunction (poor blood vessel responsiveness), low testosterone, elevated estradiol from aromatization, reduced nitric oxide availability, and the psychological effects of chronic health problems and poor body image.

Weight loss addresses most of these mechanisms simultaneously. Studies examining erectile function in obese men undergoing lifestyle-based weight loss have consistently shown improvements in erectile function scores, with the degree of improvement generally proportional to the degree of weight loss. GLP-1-mediated weight loss would be expected to produce similar benefits through the same mechanisms, though large trials specifically measuring erectile outcomes on GLP-1 therapy are limited.

Additionally, GLP-1 medications have been shown to improve endothelial function independent of weight loss through direct vascular effects — a mechanism that could contribute to improved erectile function even before significant weight loss has occurred.

This is not a reason to use GLP-1 medications as a primary treatment for ED — that is a conversation for urology or primary care. But for men over 50 seeking GLP-1 therapy for metabolic reasons, improvement in erectile function is a plausible and frequently reported secondary benefit.

Prostate Health: What GLP-1 Medications Do Not Affect

Men over 50 reasonably ask whether GLP-1 medications affect prostate health — either benign prostatic hyperplasia (BPH) or prostate cancer risk. The current evidence shows no known mechanism by which GLP-1 receptor agonists directly affect prostate tissue, and clinical trials have not identified increased rates of prostate pathology in GLP-1 treatment groups.

Obesity is independently associated with more aggressive prostate cancer behavior through hormonal and inflammatory mechanisms, and weight loss may have long-term prostate health benefits — but these are effects of weight change, not direct medication effects. Men over 50 should continue age-appropriate prostate cancer screening (PSA, digital rectal exam) per their primary care physician’s recommendation regardless of GLP-1 treatment status.

Strength Preservation: Non-Negotiable for Men Over 50

Sarcopenia — age-related muscle loss — accelerates after age 50 and is a major driver of functional decline, fall risk, and metabolic deterioration in older men. GLP-1 medications produce weight loss that includes both fat mass and lean mass, and the lean mass component can be particularly significant without intentional countermeasures.

For men over 50, the resistance training prescription is the same as for younger patients, but the stakes are higher. Skeletal muscle mass is not just about appearance or athletic performance — it is the substrate of physical independence, glucose regulation, and longevity. Men who enter their 60s with adequate muscle mass are dramatically better positioned for healthy aging than those who do not, regardless of their fat mass status.

The practical prescription: 3 sessions of resistance training per week, compound movements, progressive overload (gradually increasing resistance over time), and protein intake of 1.0-1.2g per kilogram of ideal body weight daily. Our detailed guide to preserving muscle on GLP-1 covers the evidence and specific exercise recommendations in full.

Health Span, Not Just Weight Loss: The Right Frame for This Demographic

For men in their 50s and 60s, the motivation for weight loss is increasingly about health span — the period of life spent in good health, functional independence, and reasonable quality of life — rather than aesthetics. This is a more durable motivation, and it aligns well with what the clinical evidence actually supports GLP-1 medications delivering: reduced cardiovascular event risk, improved metabolic markers, better mobility, and the secondary benefits described above.

The question to ask at this age is not “will this make me look better?” but “will this help me be healthier and more functional over the next 20 years?” For many men over 50 with visceral obesity, metabolic syndrome, or established cardiovascular disease, the honest answer from the available evidence is yes — when implemented with appropriate medical oversight, protein-forward nutrition, and resistance training.

Scale Solutions and Men Over 50

Dr. Gates has been treating metabolic disease in adult patients since 1999 and is experienced in the clinical nuances of this demographic. Initial evaluation includes a comprehensive metabolic panel, lipid panel, hemoglobin A1c, and cardiovascular risk assessment. For patients with established cardiovascular disease, collaboration with cardiology is discussed as appropriate.

For men interested in tirzepatide specifically — which targets both GLP-1 and GIP receptors and has shown somewhat greater weight loss in clinical trials than semaglutide alone — see our tirzepatide overview page. For all three Scale Solutions locations including Savannah, Pooler, and Hinesville, visit the locations page.

This page is for informational purposes only and is not medical advice. Consult Dr. Gates or another qualified clinician before starting any treatment.